Substituted heterocyclic compounds and methods of use

Details Substituted heterocyclic compounds and methods of use Substituted heterocyclic compounds and methods of use

2006-04-11

2006-04-11

Wilson, James O. (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S242000

Reexamination Certificate

active

07026326

ABSTRACT:
The present invention relates to compounds having the general formulaor a pharmaceutically acceptable salt thereof, wherein R1is a saturated or unsaturated 5-, 6- or 7-membered, ring containing 0, 1, 2 or 3 atoms selected from N, O and S, wherein the ring may be fused with a benzo group, and is substituted by 0, 1 or 2 oxo groups, and wherein R1is additionally substituted; and R2is a substituted C1-6alkyl. Also included is a method of prophylaxis or treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.

REFERENCES:
patent: 6096753 (2000-08-01), Spohr et al.
patent: 6410729 (2002-06-01), Spohr et al.
patent: 2004/0116429 (2004-06-01), Grote et al.
patent: WO 95/09917 (1995-04-01), None
patent: WO 96/18412 (1996-06-01), None
patent: WO 97/28828 (1997-08-01), None
patent: WO 97/44453 (1997-11-01), None
patent: WO 98/24477 (1998-06-01), None
patent: WO 98/24780 (1998-06-01), None
patent: WO 98/24782 (1998-06-01), None
patent: WO 98/31820 (1998-07-01), None
patent: WO 98/46257 (1998-10-01), None
“Studies on anti-platelet agents. IV. A series of 20substituted 4,5-bis(4-methoxyphenyl)pyrimidines as Novel anti-platelet agents.” Tanaka et al., Chem. Parm. Bull, vol. 42(9), (1994), pp. 1828-1830, 1834.
Loetscher, et al., “Efficacy of a chimeric TNFR-IgG fusin protein to inhibit TNF activity in animal models of septic shock.” International Congress Series, 2: 455-462 (1993).
Brocks, et al., “A TNF receptor antagonistic scFv, which is not secreted in mammalian cells, is expressed as a soluble mono-and bivalent scFv derivative in insect cells.” Immunotechnology, 3: 173-184 (1997).

Affiliated with

Also associated with

Rating

Substituted heterocyclic compounds and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted heterocyclic compounds and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted heterocyclic compounds and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3604815